Why the study?
Aspirin's role in primary prevention has become controversial as contemporary trials suggest diminishing benefit, no reduction in hard outcomes, and potential for harm.
Does aspirin reduce cardiovascular events in primary and secondary prevention in the modern era?
Does aspirin reduce cardiovascular events in primary and secondary prevention in the modern era?
This review highlights the diminishing benefit and potential harm of aspirin for primary cardiovascular prevention in the modern era of improved risk factor control.
Answers are grounded in this paper and cite their sources.
May support avoiding routine aspirin in primary prevention; leaves open its role in secondary prevention amid modern risk factor control.
monotherapy group. In contrast to secondary prevention, aspirin's role in primary prevention has always been more controversial. While historical trials reported a reduction in MI and stroke, more contemporary trials have suggested diminishing benefit for aspirin in this setting, with no reduction in hard outcomes, and some primary prevention trials have even indicated a potential for harm. In this review, we discuss how changing population demographics, enhanced control of lipids and blood pressure, changes in the definition of outcomes like MI, evolution of aspirin formulations, and updated clinical practice guidelines have all impacted the use of aspirin for primary and secondary CVD prevention.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: